Rett Syndrome Clinical Trial
Official title:
A Pilot Study of an Antioxidant Cocktail vs. Placebo in the Treatment of Children and Adolescents With Rett Syndrome
This study will examine the potential efficacy and safety of Rett-T for core motor deficits of Rett syndrome, and will explore biological markers of safety and treatment response.
There are currently no available medicines shown to be effective for Rett syndrome. Numerous
studies implicate mitochondrial dysfunction and oxidative stresses in the pathophysiology of
Rett syndrome. Mitochondrial dysfunction has been reported in Rett patients, Rett mouse
models and MECP2-deficient cells.
Collaborators have tested a combination of specific antioxidants known to enhance
mitochondrial function in a cell and mouse model of Rett syndrome. The formulation normalized
mitochondrial membrane potential in MECP2 neurons, and MECP2-deficient mice displayed
improved exploratory, locomotor and social behavior compared to MECP2-deficient mice. These
results support testing anti-oxidative strategies for benefit in individuals with Rett
syndrome.In this study, the formulation has been adjusted and optimized based on current
guidelines for human use, with the goal of translating a potential new treatment from the
animal model to use in humans. Results of this study could lead to the first approved
medication treatment for the disorder.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04988867 -
An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome
|
Phase 2/Phase 3 | |
| Recruiting |
NCT00069550 -
Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome
|
Phase 3 | |
| Enrolling by invitation |
NCT06139172 -
Promoting Prosocial Behavior in Syndromic Intellectual and Developmental Disabilities
|
N/A | |
| Not yet recruiting |
NCT04014985 -
Patients With RETT Syndrome
|
N/A | |
| Completed |
NCT02705677 -
Biobanking of Rett Syndrome and Related Disorders
|
||
| Terminated |
NCT02790034 -
Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms
|
Phase 2/Phase 3 | |
| Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
| Recruiting |
NCT05932589 -
Neurophysiologic Biomarkers in Rett Syndrome
|
||
| Recruiting |
NCT04463316 -
GROWing Up With Rare GENEtic Syndromes
|
||
| Completed |
NCT04776746 -
Open-Label Extension Study of Trofinetide for Rett Syndrome
|
Phase 3 | |
| Completed |
NCT04181723 -
Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)
|
Phase 3 | |
| Enrolling by invitation |
NCT03836300 -
Parent and Infant Inter(X)Action Intervention (PIXI)
|
N/A | |
| Completed |
NCT04514549 -
ASSESSING EMERALD AND MC10 BIOSTAMP nPOINT BIOSENSORS FOR RETT SYNDROME
|
||
| Terminated |
NCT02562820 -
An Exploratory Trial of Ketamine for the Treatment of Rett Syndrome
|
Phase 1 | |
| Completed |
NCT02738281 -
Natural History of Rett Syndrome & Related Disorders
|
||
| Completed |
NCT05687214 -
Osteopathic Manipulative Treatment for Constipation in People With Rett Syndrome
|
N/A | |
| Recruiting |
NCT06199700 -
Esketamine for the Treatment of Rett Syndrome
|
Early Phase 1 | |
| Completed |
NCT03941444 -
ANAVEX2-73 Study in Patients With Rett Syndrome
|
Phase 3 | |
| Recruiting |
NCT06346106 -
The Diagnostic Experience of Male Rett Syndrome
|
||
| Not yet recruiting |
NCT06338267 -
Validation of Innovative Biosensors for Rett Autonomic Symptom Tracking
|